Photodynamic Therapy with Verteporfin in Treatment of Wet Form ARMD – Long Term Results


Authors: D. Vysloužilová ;  P. Kolář ;  V. Matušková ;  E. Vlková
Authors‘ workplace: Oční klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice, Brno, přednosta prof. MUDr. Eva Vlková, CSc.
Published in: Čes. a slov. Oftal., 68, 2012, No. 3, p. 98-101
Category: Original Article

Overview

Photodynamic therapy with Verteporfin (Visudyne - Novartis AG, Basel, Switzerland) is a method designed for treatment of the wet form of age-related macular degeneration.

Effectiveness of photodynamic therapy with Verteporfin we approved on our department in group of 301 patients (114 males, 187 women) of average age 73.5 years with predominantly classic choroidal neovascular membrane in subfoveal localization in wet form of age-related macular degeneration. The follow up period in this group was from 6 to 36 month (mean 21 months).

Patients with predominantly classic choroidal neovascular membrane underwent during the observation period from 1 to 5 treatments (mean 1.45 treatments). Mean best corrected visual acuity was before treatment 0.708 ± 0.24 logMAR. At the end of three-year observation period was the mean best corrected visual acuity 1.016 ± 0.36 logMAR. Best corrected visual acuity dropped during this time by 3.08 lines (15.4 letters) of ETDRS (early treatment diabetic retinopathy study) visual charts.

Decrease of mean best corrected visual acuity less than 3 lines on ETDRS charts is considered as stabilisation. This goal was achieved in our group during observation period in 2/3 of patients.

Key words:
age-related macular degeneration, choroidal neovascular membrane, fluorescein angiography, photodynamic therapy with verteporfin


Sources

1. Alliston, BA, Protchard, PH, Levy, JG.: Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivate. Br J Cancer, 1994; 69: 833–839.

2. Coscas, G., Coscas, F., Soubrane, G.: Monitoring the patient after treatment: Angiographic aspect of recurrence and indications for retreatment. J Fr Ophthalmol, 2004; 27: 81–92.

3. Eye Disease Case-Control Study Group: Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol, 1992; 110: 104–109.

4. Heiba, IM, Elston, RC, Klein, BE et al.: Correlations and segregation analysis of age-related maculopathy: the Beaver Eye Dam Study. Genet Epidemiol, 1994; 11: 51–67.

5. Klein, R, Klein, BEK, Linton, KLP: Prevalence of age-related maculopathy: the Beaver Eye Dam Study. Ophthalmology, 1992; 99: 933–944.

6. Kolář P. a kol. Věkem podmíněná makulární degenerace. Praha, Grada, 2008.

7. Kolář, P., Vlková, E., Vižďová, D.: Fotodynamická terapie s preparátem Visudyne v léčbě vlhké formy věkem podmíněné makulární degenerace – dvouleté výsledky. Čas. Lék. Čes, 2006; 145: 795–800.

8. Schmidt-Erfurth, U, Hassan, T.: Mechanism of action of photodynamic therapy with verteporfin for treatment of age-related macular degeneration. Surv Ophthalmol, 2000; 45: 195–214.

9. Schmidt-Erfurth, U., Miller, JW., Sickenberg, M. et al.: Photodynamic therapy with verteporfin for chorioideal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol, 1999; 117: 1177–1187.

10. Soubrane, G., Kuhn, D., Coscas, G.: Indications for photodynamic therapy in age-related macular degeneration. J Fr Ophthalmol, 2004; 27: 79–80.

Labels
Ophthalmology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account